Rainbow Table Reference List

7/30/2019 Rainbow Table Reference List

1/28

Rainbow Table Reference List-1

Rainbow Table Reference List

Preclinical Candidates..2

Clinical Candidates..5

Inactive or Discontinued Candidates.16


2/28


Pre-Clinical Malaria Vaccine References

References are listed chronologically

P27A

Olugbile S, Kulangara C, Bang G, Bertholet S, Suzarte E, Villard V, et al. Vaccine

potentials of an intrinsically unstructured fragment derived from the blood stage-

associated Plasmodium falciparum protein PFF0165c. Infect.Immun. 2009Dec;77(12):5701-5709.

pfAMA1 DiCo

Remarque EJ, Faber BW, Kocken CH, Thomas AW. A diversity-covering approach to

immunization with Plasmodium falciparum apical membrane antigen 1 induces broader

allelic recognition and growth inhibition responses in rabbits. Infect.Immun. 2008

Jun;76(6):2660-2670.

PAM VAR2CSA

Barfod L, Nielsen MA, Turner L, Dahlback M, Jensen AT, Hviid L, et al. Baculovirus-

expressed constructs induce immunoglobulin G that recognizes VAR2CSA onPlasmodium falciparum-infected erythrocytes. Infect.Immun. 2006 Jul;74(7):4357-4360.

Salanti A, Resende M, Ditlev SB, Pinto VV, Dahlback M, Andersen G, et al. Severaldomains from VAR2CSA can induce Plasmodium falciparum adhesion-blocking

antibodies. Malar J. 2010 Jan 11;9:11.

Var2-CSA DBL2/3-X

Srivastava A, Gangnard S, Round A, Dechavanne S, Juillerat A, Raynal B, et al. Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific,

high-affinity binding to CSA. Proc.Natl.Acad.Sci.U.S.A. 2010 Mar 16;107(11):4884-

4889.

NMRC-M3V-Ad-Pf5

No citation.

CSVAC

No citation.

Pf CelTOS FMP012

Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M,Ockenhouse C, et al. Immunization with pre-erythrocytic antigen CelTOS from


3/28


Plasmodium falciparum elicits cross-species protection against heterologous challenge

with Plasmodium berghei. PLoS One 2010 Aug 19;5(8):e12294.

Ad35.CS.01/Ad26.CS.01 (Heterologous adenovirus prime-boost strategy)

No citation.

Two-component paediatric malaria vaccine (CS, LSA-1, STARP)

No citation.

Pf GAP p52-/p32- (Genetically Attenuated Sporozoites)

VanBuskirk KM, O'Neill MT, De La Vega P, Maier AG, Krzych U, Williams J, DowlerMG, Sacci JB Jr, Kangwanrangsan N, Tsuboi T, Kneteman NM, Heppner DG Jr,

Murdock BA, Mikolajczak SA, Aly AS, Cowman AF, Kappe SH. Preerythrocytic, live-

attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S

A. 2009 Aug 4;106(31):13004-9

MSP1 full length

No citation.

Pfs25-rEPA/Alhydrogel

Qian F, Wu Y, Muratova O, Zhou H, Dobrescu G, Duggan P, et al. Conjugating

recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing

immunogenicity of malaria vaccine candidates. Vaccine 2007 May 16;25(20):3923-3933.

Qian F, Rausch KM, Muratova O, Zhou H, Song G, Diouf A, et al. Addition of CpGODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and

Pfs25 greatly increases the number of responders. Vaccine 2008 May 12;26(20):2521-

2527.

Pfs25-Pfs25 conjugate vaccine

Kubler-Kielb J, Majadly F, Biesova Z, Mocca CP, Guo C, Nussenzweig R, et al. Abicomponent Plasmodium falciparum investigational vaccine composed of protein-

peptide conjugates. Proc.Natl.Acad.Sci.U.S.A. 2010 Jan 19;107(3):1172-1177.

SR11.1

No citation.

Pfs48/45

Outchkourov NS, Roeffen W, Kaan A, Jansen J, Luty A, Schuiffel D, et al. Correctly

folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blockingimmunity in mice Proc.Natl.Acad.Sci.U.S.A. 2008 Mar 18;105(11):4301-4305.


4/28


NMRC-M3V-Ad-PfCA in Adjuvant (7DW8-5)

Li X, Fujio M, Imamura M, Wu D, Vasan S, Wong CH, et al. Design of a potent CD1d-

binding NKT cell ligand as a vaccine adjuvant Proc.Natl.Acad.Sci.U.S.A. 2010 Jul

20;107(29):13010-13015.


5/28


Clinical Malaria Vaccine References


RTS,S/AS01E

Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, et al.Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium

falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect

Dis 1995 Jun;171(6):1576-85.

Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A

preliminary evaluation of a recombinant circumsporozoite protein vaccine against

Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group [see

comments]. N Engl J Med 1997;336(2):86-91.

Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, et al. Long-term efficacyand immune responses following immunization with the RTS,S malaria vaccine. J Infect

Dis 1998;178(4):1139-44.

Doherty JF, Pinder M, Tornieporth N, Carton C, Vigneron L, Milligan P, et al. A phase Isafety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in

semi-immune adults in The Gambia. Am J Trop Med Hyg 1999;61(6):865-8.

Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, et al. Potent induction of

focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a

recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 1999;180(5):1656-64.

Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, et al.

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental

Plasmodium falciparum malaria. J Infect Dis 2001;183(4):640-7.

Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, et al. Efficacyof RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-

immune adult men in The Gambia: a randomised trial. Lancet 2001 Dec

8;358(9297):1927-34.

Garcon N, Heppner DG, Cohen J. Development of RTS,S/AS02: a purified subunit-based

malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2003Apr;2(2):231-8.

Schwenk R, Asher LV, Chalom I, Lanar D, Sun P, White K, et al. Opsonization by

antigen-specific antibodies as a mechanism of protective immunity induced by

Plasmodium falciparum circumsporozoite protein-based vaccine. Parasite Immunol 2003

Jan;25(1):17-25.


6/28


Alloueche A, Milligan P, Conway DJ, Pinder M, Bojang K, Doherty T, et al. Protective

efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific.

Am J Trop Med Hyg 2003;68(1):97-101.

Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, et al. Protective immunity

induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparumcircumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J

Immunol 2003 Dec 15;171(12):6961-7.

Pinder M, Reece WH, Plebanski M, Akinwunmi P, Flanagan KL, Lee EA, et al. Cellular

immunity induced by the recombinant Plasmodium falciparum malaria vaccine,RTS,S/AS02, in semi-immune adults in The Gambia. Clin Exp Immunol

2004;135(2):286-93.

Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the

RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young

African children: randomised controlled trial. Lancet 2004 Oct 16;364(9443):1411-20.

Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, et al. Duration of

protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum

disease in Mozambican children: single-blind extended follow-up of a randomised

controlled trial. Lancet 2005 Dec 10;366(9502):2012-2018.

Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, et al.

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian

children. Vaccine 2005 Jul 14;23(32):4148-4157.

Heppner DG,Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, et al.Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria:

progress at the Walter Reed Army Institute of Research. Vaccine 2005 Mar 18;23(17-

18):2243-50.

Stoute JA, Heppner DG,Jr, Mason CJ, Siangla J, Opollo MO, Kester KE, et al. Phase 1safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a

hyperendemic region of western Kenya. Am.J.Trop.Med.Hyg. 2006 Jul;75(1):166-170.

Enosse S, Dobano C, Quelhas D, Aponte JJ, Lievens M, Leach A, et al. RTS,S/AS02Amalaria vaccine does not induce parasite CSP T cell epitope selection and reduces

multiplicity of infection. PLoS Clin Trials 2006 May;1(1):e5.

Macete EV, Sacarlal J, Aponte JJ, Leach A, Navia MM, Milman J, et al. Evaluation oftwo formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years

living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-

blind bridging trial. Trials 2007;8:11.


7/28


Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, G. HD,Jr, Hall T, et al. A

phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine

RTS,S/AS02A in malaria-naive adults. Vaccine 2007 Jul 20;25(29):5359-66.

Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, et al. Priming withan adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01Bboosting significantly improves immunogenicity to Plasmodium falciparum CS compared

to that with either malaria vaccine alone. Infect Immun 2007 May;75(5):2283-90.

Macete E, Aponte JJ, Guinovart C, Sacarlal J, Ofori-Anyinam O, Mandomando I, et al.Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children

aged 1-4 in Mozambique. Trop.Med.Int.Health 2007 Jan;12(1):37-46.

Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, et al. Safety of the

RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of

Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007 Nov3;370(9598):1543-51.

Bejon P, Lusingu J, Olutu A. Efficacy of the RTS,S/AS01E vaccine against clinical

episodes of falciparum malaria in 5 to 17 month old children in Kenya and Tanzania. N

Engl J Med 2008 2008.

Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, Gordon DM, et al. Phase

2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria

vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of

Research. Vaccine 2008 Apr 24;26(18):2191-202.

Abdulla S, Oberholzer R, Juma O, Kubhoja S. Safety and Immunogenicity of

RTS,S/AS02D Malaria Vaccine in Infants. N Engl J Med 2008.

Sacarlal J, Aponte JJ, Aide P, Mandomando I, Bassat Q, Guinovart C, et al. Safety of the

RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine

2008 Jan 10;26(2):174-184.

Ballou WR. The development of the RTS,S malaria vaccine candidate: challenges and

lessons. Parasite Immunol 2009 Sep;31(9):492-500.

Vekemans J, Leach A, Cohen J. Development of the RTS,S/AS malaria candidatevaccine. Vaccine 2009 Dec 30;27 Suppl 6:G67-71.

Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, Apollo S, et al.

Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission

area. PLoS One 2009;4(7):e6465.


8/28


Bojang K, Milligan P, Pinder M, Doherty T, Leach A, Ofori-Anyinam O, et al. Five-year

safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02following administration to semi-immune adult men living in a malaria-endemic region

of The Gambia. Hum Vaccin 2009 Apr;5(4):242-7.

Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From thecircumsporozoite protein to the RTS,S/AS candidate vaccine. Hum Vaccin 2009 Jan

30;6(1).

Olotu AI, Fegan G, Bejon P. Further analysis of correlates of protection from a phase 2a

trial of the falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-

naive adults. J Infect Dis 2009 Mar 15;201(6):970-1.

Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by

RTS,S: a review of the available data. Malar J 2009;8(1):312.

Waitumbi JN, Anyona SB, Hunja CW, Kifude CM, Polhemus ME, Walsh DS, et al.Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults

participating in a malaria vaccine clinical trial. PLoS One 2009 Nov 17;4(11):e7849.

Guinovart C, Aponte JJ, Sacarlal J, Aide P, Leach A, Bassat Q, et al. Insights into long-

lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase

IIb trial in Mozambican children. PLoS One 2009;4(4):e5165.

Sacarlal J, Aide P, Aponte JJ, Renom M, Leach A, Mandomando I, et al. Long-termsafety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.

J.Infect.Dis. 2009 Aug 1;200(3):329-336.

Barbosa A, Naniche D, Aponte JJ, Manaca MN, Mandomando I, Aide P, et al. P.falciparum specific cellular immune responses after immunization with the

RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of

Mozambique. Infect Immun 2009 Aug 3.

Owusu-Agyei S, Ansong D, Asante K, Kwarteng Owusu S, Owusu R, Wireko BrobbyNA, et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria

candidate vaccines given according to different schedules in Ghanaian children. PLoS

One 2009 Oct 2;4(10):e7302.

Lell B, Agnandji S, von Glasenapp I, Haertle S, Oyakhiromen S, Issifou S, et al. Arandomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted

RTS,S malaria vaccine candidates in children in Gabon. PLoS One 2009 Oct

27;4(10):e7611.

Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al.Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B


9/28


and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates

of protection. J Infect Dis 2009 Aug 1;200(3):337-46.

Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R, et al.

Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate

vaccine when integrated in the expanded program of immunization J.Infect.Dis. 2010 Oct1;202(7):1076-1087.

Olotu AI, Fegan G, Bejon P. Further analysis of correlates of protection from a phase 2atrial of the falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-

naive adults J.Infect.Dis. 2010 Mar 15;201(6):970-971.

Vahey MT, Wang Z, Kester KE, Cummings J, Heppner DG,Jr, Nau ME, et al. Expression

of genes associated with immunoproteasome processing of major histocompatibilitycomplex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine

J.Infect.Dis. 2010 Feb 15;201(4):580-589.


10/28


AdCh63/MVA ME-TRAP

Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors

enhances the durability and polyfunctionality of protective malaria CD8+ T-cell

responses. Infect.Immun. 2010 Jan;78(1):145-153.

Adenovirus (Ad35) vectored CS

Marzio G, Kerkvliet E, Bogaards JA, Koelewijn S, De Groot A, Gijsbers L, et al. A

replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6cells. Vaccine 2007 Mar 8;25(12):2228-2237.

Shott JP, McGrath SM, Pau MG, Custers JH, Ophorst O, Demoitie MA, et al. Adenovirus5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein

elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice.

Vaccine 2008 Jun 2;26(23):2818-23.

PfSPZ: metabolically active, non-replicating malaria sporozoite vaccine

Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection ofhumans against malaria by immunization with radiation-attenuated Plasmodium

falciparum sporozoites. J.Infect.Dis. 2002 Apr 15;185(8):1155-1164.

Luke TC, Hoffman SL. Rationale and plans for developing a non-replicating,metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J

Exp Biol 2003 Nov;206(Pt 21):3803-8.

Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, et al.Development of a metabolically active, non-replicating sporozoite vaccine to prevent

Plasmodium falciparum malaria. Hum.Vaccin 2010 Jan;6(1):97-106.

AdCh63/MVA MSP1

Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, et al. Effective

induction of high-titer antibodies by viral vector vaccines. Nat Med 2008 Aug;14(8):819-

21.

Draper SJ, Goodman AL, Biswas S, Forbes EK, Moore AC, Gilbert SC, et al.Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- andT cell-mediated multistage protection against malaria Cell.Host Microbe 2009 Jan

22;5(1):95-105.

Douglas AD, de Cassan SC, Dicks MD, Gilbert SC, Hill AV, Draper SJ. Tailoring

subunit vaccine immunogenicity: maximizing antibody and T cell responses by using


11/28


combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium

falciparum MSP1 Vaccine 2010 Oct 18;28(44):7167-7178.

Goodman AL, Epp C, Moss D, Holder AA, Wilson JM, Gao GP, et al. New candidate

vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization

regimens incorporating human and simian adenoviral vectors and poxviral vectorsexpressing an optimized antigen based on merozoite surface protein 1 Infect.Immun.

2010 Nov;78(11):4601-4612.

EBA175 RII

Fouda GG, Leke RF, Long C, Druilhe P, Zhou A, Taylor DW, et al. Multiplex assay for

simultaneous measurement of antibodies to multiple Plasmodium falciparum antigens

Clin.Vaccine Immunol. 2006 Dec;13(12):1307-1313.

Peek LJ, Brandau DT, Jones LS, Joshi SB, Middaugh CR. A systematic approach to

stabilizing EBA-175 RII-NG for use as a malaria vaccine. Vaccine 2006 Jul 26;24(31-32):5839-5851.

Peek LJ, Martin TT, Elk Nation C, Pegram SA, Middaugh CR. Effects of stabilizers on

the destabilization of proteins upon adsorption to aluminum salt adjuvants J.Pharm.Sci.

2007 Mar;96(3):547-557.

El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, Thompson D, et al. Safety and

immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175

Region II malaria vaccine in healthy adults living in an area where malaria is not endemic

Clin.Vaccine Immunol. 2010 Oct;17(10):1552-1559.

FMP2.1/AS02A (AMA-1 3D7 E. coli-expressed in AS02A adjuvant)

Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, Vassell MA, et al. Purification,characterization, and immunogenicity of the refolded ectodomain of the Plasmodium

falciparum apical membrane antigen 1 expressed in Escherichia coli Infect.Immun. 2002Jun;70(6):3101-3110.

Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, et al.Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical

membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at

the Walter Reed Army Institute of Research. Vaccine 2007 May 22;25(21):4203-4212.

Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, Guindo AB, et al. Safety

and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1

randomized controlled trial. PLoS One 2008 Jan 23;3(1):e1465.

Lyke KE, Daou M, Diarra I, Kone A, Kouriba B, Thera MA, et al. Cell-mediatedimmunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in


12/28


Malian adults: results of a Phase I randomized trial. Vaccine 2009 Mar 26;27(15):2171-

2176.

Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, Guindo AB, et al. Safety

and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1

randomized controlled trial. PLoS One 2010 Feb 4;5(2):e9041.

FMP2.1/AS01B (AMA-1 3D7 E. coli expressed in ASO1B adjuvant)

Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, et al. Phase1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1)

administered in adjuvant system AS01B or AS02A. PLoS One 2009;4(4):e5254.

FMP010/AS01B (MSP-1 42 FVO E. coli-expressed in AS01B adjuvant)

Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE,

et al. Development and pre-clinical analysis of a Plasmodium falciparum MerozoiteSurface Protein-1(42) malaria vaccine. Mol.Biochem.Parasitol. 2003 May;128(2):195-

204.

GMZ2

Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, et al. APlasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus

lactis, immunogenicity and induction of biologically active antibodies. Vaccine 2004 Mar

12;22(9-10):1188-1198.

Carvalho LJ, Alves FA, Bianco C,Jr, Oliveira SG, Zanini GM, Soe S, et al. Immunizationof Saimiri sciureus monkeys with a recombinant hybrid protein derived from the

Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3can induce partial protection with Freund and Montanide ISA720 adjuvants.

Clin.Diagn.Lab.Immunol. 2005 Feb;12(2):242-248.

Esen M, Kremsner PG, Schleucher R, Gassler M, Imoukhuede EB, Imbault N, et al.

Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine

candidate. Vaccine 2009 Nov 16;27(49):6862-6868.

Mordmuller B, Szywon K, Greutelaers B, Esen M, Mewono L, Treut C, et al. Safety and

immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adultindividuals from Lambarene, Gabon. Vaccine 2010 Aug 6.

MSP3 [181-276]

Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, et al. Phase I malaria vaccinetrial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Infect.Immun. 2005 Dec;73(12):8017-8026.


13/28


Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, Singh S, et al. A malaria vaccine

that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2005Nov;2(11):e344.

Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, et al. Safety and

immunogenicity of the Plasmodium falciparum merozoite surface protein-3 longsynthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in

Burkina Faso, West Africa. Vaccine 2007 Mar 30;25(14):2723-2732.

Lusingu JP, Gesase S, Msham S, Francis F, Lemnge M, Seth M, et al. Satisfactory safety

and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-

24 months. Malar J. 2009 Jul 17;8:163.

Nebie I, Diarra A, Ouedraogo A, Tiono AB, Konate AT, Gansane A, et al. Humoral andcell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria

endemic area, Burkina Faso. Parasite Immunol. 2009 Aug;31(8):474-480.

Sirima SB, Tiono AB, Ouedraogo A, Diarra A, Ouedraogo AL, Yaro JB, et al. Safety andimmunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24

months-old Burkinabe children. PLoS One 2009 Oct 26;4(10):e7549.

SE36

Horii T, Shirai H, Jie L, Ishii KJ, Palacpac NQ, Tougan T, et al. Evidences of protectionagainst blood-stage infection of Plasmodium falciparum by the novel protein vaccine

SE36. Parasitol.Int. 2010 Sep;59(3):380-386.

NMRC-M3V-Ad-PfCA

Sedegah M, Kim Y, Peters B, McGrath S, Ganeshan H, Lejano J, et al. Identification and

localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodiumfalciparum AMA1 protein. Malar J. 2010 Aug 24;9(1):241.

NMRC-M3V-D/Ad- PfCA Prime/Boost

No citation.

AMA1-C1/Alhydrogel+ CPG 7909

Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, et al. Phase1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for

Plasmodium falciparum malaria. Infect.Immun. 2005 Jun;73(6):3677-3685.

Mullen GE, Giersing BK, Ajose-Popoola O, Davis HL, Kothe C, Zhou H, et al.

Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodiumfalciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 2006 Mar

24;24(14):2497-2505.


14/28


Dicko A, Diemert DJ, Sagara I, Sogoba M, Niambele MB, Assadou MH, et al. Impact of

a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS

One 2007 Oct 17;2(10):e1045.

Mullen GE, Aebig JA, Dobrescu G, Rausch K, Lambert L, Long CA, et al. Enhanced

antibody production in mice to the malaria antigen AMA1 by CPG 7909 requiresphysical association of CpG and antigen. Vaccine 2007 Jul 20;25(29):5343-5347.

Qian F, Wu Y, Muratova O, Zhou H, Dobrescu G, Duggan P, et al. Conjugatingrecombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing

immunogenicity of malaria vaccine candidates. Vaccine 2007 May 16;25(20):3923-3933.

Dicko A, Sagara I, Ellis RD, Miura K, Guindo O, Kamate B, et al. Phase 1 study of a

combination AMA1 blood stage malaria vaccine in Malian children. PLoS One 2008 Feb

13;3(2):e1563.

Mullen GE, Ellis RD, Miura K, Malkin E, Nolan C, Hay M, et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium

falciparum malaria. PLoS One 2008 Aug 13;3(8):e2940.

Qian F, Rausch KM, Muratova O, Zhou H, Song G, Diouf A, et al. Addition of CpG

ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 andPfs25 greatly increases the number of responders. Vaccine 2008 May 12;26(20):2521-

2527.

Crompton PD, Mircetic M, Weiss G, Baughman A, Huang CY, Topham DJ, et al. The

TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory

B cells in malaria-naive individuals. J.Immunol. 2009 Mar 1;182(5):3318-3326.

Ellis RD, Mullen GE, Pierce M, Martin LB, Miura K, Fay MP, et al. A Phase 1 study of

the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using

two different formulations and dosing intervals. Vaccine 2009 Jun 24;27(31):4104-4109.

Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, et al. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1

antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro

growth inhibition assay. Clin.Vaccine Immunol. 2009 Jul;16(7):963-968.

Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, et al. A randomizedcontrolled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in

children in Mali. Vaccine 2009 May 18;27(23):3090-3098.

Sagara I, Ellis RD, Dicko A, Niambele MB, Kamate B, Guindo O, et al. A randomized

and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune

Malian adults. Vaccine 2009 Dec 9;27(52):7292-7298.


15/28


Ouattara A, Mu J, Takala-Harrison S, Saye R, Sagara I, Dicko A, et al. Lack of allele-

specific efficacy of a bivalent AMA1 malaria vaccine. Malar J. 2010 Jun 21;9:175.

BSAM-2/Alhydrogel+CPG 7909

No citation.

CSP, AMA1 virosomes (PEV 301,302)

Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, et al. A

randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated

synthetic peptides in healthy adult volunteers. PLoS One 2007 Oct 10;2(10):e1018.

Okitsu SL, Silvie O, Westerfeld N, Curcic M, Kammer AR, Mueller MS, et al. A

virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody

response in a phase 1a clinical trial. PLoS ONE 2007;2(12):e1278.

VMP001/AS01B

Bell BA, Wood JF, Bansal R, Ragab H, Cargo J,3rd, Washington MA, et al. Process

development for the production of an E. coli produced clinical grade recombinant malaria

vaccine for Plasmodium vivax. Vaccine 2009 Feb 25;27(9):1448-1453.

AdCh63 AMA1/MVA AMA1

No citation.

polyepitope DNA EP1300

No citation.

JAIVAC (MSP1 19/EBA175)

No citation.


16/28


Inactive or Discontinued Malaria Vaccine References


RTS,S/AS02A

See RTS,S/AS01E on Clinical Sheet

GLURP [85-213]

Hermsen CC, Verhage DF, Telgt DS, Teelen K, Bousema JT, Roestenberg M, et al.

Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth ofPlasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 2007 Apr

12;25(15):2930-2940.

AMA1-FVO [25-545]

Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O, et al.

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malariavaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One

2008;3(12):e3960.

FP9/MVA Polyprotein

Prieur E, Gilbert SC, Schneider J, Moore AC, Sheu EG, Goonetilleke N, et al. A

Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded byrecombinant poxviruses. Proc.Natl.Acad.Sci.U.S.A. 2004 Jan 6;101(1):290-295.

FMP011/AS01B (LSA-1 E. coli-expressed in AS01B adjuvant)

FMP011/AS02A (LSA-1 E. coli-expressed in AS02A adjuvant)

Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE,

et al. Development and pre-clinical analysis of a Plasmodium falciparum Merozoite

Surface Protein-1(42) malaria vaccine Mol.Biochem.Parasitol. 2003 May;128(2):195-204.

Hillier CJ, Ware LA, Barbosa A, Angov E, Lyon JA, Heppner DG, et al. Process

development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based

vaccine for Plasmodium falciparum. Infect.Immun. 2005 Apr;73(4):2109-2115.

Brando C, Ware LA, Freyberger H, Kathcart A, Barbosa A, Cayphas S, et al. Murine

immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate,delivered with adjuvant AS01B or AS02A. Infect.Immun. 2007 Feb;75(2):838-845.


17/28


Pichyangkul S, Kum-Arb U, Yongvanitchit K, Limsalakpetch A, Gettayacamin M, Lanar

DE, et al. Preclinical evaluation of the safety and immunogenicity of a vaccine consistingof Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone

or concurrently with the RTS,S/AS01B vaccine in rhesus primates. Infect.Immun. 2008

Jan;76(1):229-238.

Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, et

al. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe,

elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does notprotect against experimental Plasmodium falciparum infection. Vaccine 2010 Jul

12;28(31):5135-5144.

FMP1/AS02A (MSP-1 42 3D7 E. coli-expressed in AS02A adjuvant)

Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, et al. Phase Isafety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1

asexual blood stage vaccine. Vaccine 2006 Apr 5;24(15):3009-3017.

Withers MR, McKinney D, Ogutu BR, Waitumbi JN, Milman JB, Apollo OJ, et al.

Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib

dose-escalation trial in Kenyan children. PLoS Clin.Trials 2006 Nov 24;1(7):e32.

Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, et al. Safety and

allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I

randomized trial. PLoS Clin.Trials 2006 Nov 24;1(7):e34.

Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, et al. Phase 1

randomized double-blind safety and immunogenicity trial of Plasmodium falciparummalaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in

western Kenya. Vaccine 2007 Jan 2;25(1):176-84.

Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, et al. Blood stagemalaria vaccine eliciting high antigen-specific antibody concentrations confers no

protection to young children in Western Kenya. PLoS ONE 2009;4(3):e4708.

MSP1-C1/AlOH/AlOH + CpG

Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O, et al. Efficacy of two

alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an

Aotus challenge trial. Infect.Immun. 2001 Mar;69(3):1536-1546.

Stowers AW, Chen Lh LH, Zhang Y, Kennedy MC, Zou L, Lambert L, et al. A

recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeysfrom a lethal challenge with Plasmodium falciparum. Proc.Natl.Acad.Sci.U.S.A. 2002

Jan 8;99(1):339-344.


18/28


Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW. Biochemical andimmunological characterization of bacterially expressed and refolded Plasmodiumfalciparum 42-kilodalton C-terminal merozoite surface protein 1. Infect.Immun. 2003

Dec;71(12):6766-6774.

Singh S, Miura K, Zhou H, Muratova O, Keegan B, Miles A, et al. Immunity torecombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection inAotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro

parasite-inhibitory activity. Infect.Immun. 2006 Aug;74(8):4573-4580.

Malkin E, Long CA, Stowers AW, Zou L, Singh S, MacDonald NJ, et al. Phase 1 studyof two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum

malaria. PLoS Clin.Trials 2007;2(4):e12.

Huaman MC, Martin LB, Malkin E, Narum DL, Miller LH, Mahanty S, et al. Ex vivo

cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum

merozoite surface protein-1 in vaccinated volunteers. J.Immunol. 2008 Feb1;180(3):1451-1461.

Crompton PD, Mircetic M, Weiss G, Baughman A, Huang CY, Topham DJ, et al. The

TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memoryB cells in malaria-naive individuals. J.Immunol. 2009 Mar 1;182(5):3318-3326.




Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, Fay MP, et al. Phase 1 trial of the

Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without

CPG 7909 in malaria naive adults. PLoS One 2010 Jan 22;5(1):e8787.

MSP2-C1/ISA720

Abstract information only

http://www.astmh.org/AM/Template.cfm?Section=Meeting_Archives&Template=/CM/ContentDisplay.cfm&ContentID=2316

Abstract number 1076

AMA1-C1/ ISA720

Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, et al. In vitro studies withrecombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production

and activity of an AMA1 vaccine and generation of a multiallelic response. Infect.Immun.

2002 Dec;70(12):6948-6960.


19/28


Stowers AW, Chen Lh LH, Zhang Y, Kennedy MC, Zou L, Lambert L, et al. Arecombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys

from a lethal challenge with Plasmodium falciparum. Proc.Natl.Acad.Sci.U.S.A. 2002

Jan 8;99(1):339-344.

Giersing B, Miura K, Shimp R, Wang J, Zhou H, Orcutt A, et al. posttranslational

modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact

on functional immune responses to a malaria vaccine candidate. Infect.Immun. 2005Jul;73(7):3963-3970.




Pierce MA, Ellis RD, Martin LB, Malkin E, Tierney E, Miura K, et al. Phase 1 safety andimmunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-

C1/ISA 720 in Australian adults. Vaccine 2010 Mar 2;28(10):2236-2242.

PfCP2.9 (MSP-1 19/AMA-1 chimera)

Hu J, Chen Z, Gu J, Wan M, Shen Q, Kieny MP, et al. Safety and immunogenicity of a

malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in

montanide ISA 720 in healthy adults. PLoS ONE 2008;3(4):e1952.

Malkin E, Hu J, Li Z, Chen Z, Bi X, Reed Z, et al. A phase 1 trial of PfCP2.9: an

AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.Vaccine 2008 Dec 9;26(52):6864-6873.

DNA/MVA CS

Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, et al. A DNAprime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related

adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive

adults against Plasmodium falciparum sporozoite challenge. Infect.Immun. 2006

Oct;74(10):5933-5942.

FP9/MVA & DNA/MVA ME-TRAP

Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, Skinner MA, et al.Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month

reboosting vaccination, for malaria vaccination in gambian men. J Infect Dis 2004 Jun

15;189(12):2213-9.


20/28


Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, et al.

Differential immunogenicity of various heterologous prime-boost vaccine regimens using

DNA and viral vectors in healthy volunteers. J.Immunol. 2005 Jan 1;174(1):449-455.

Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, et al.

Enhanced T cell-mediated protection against malaria in human challenges by using therecombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S

A 2005 Mar 29;102(13):4836-41.

Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, et al. A DNA

prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-relatedadhesion protein but not circumsporozoite protein partially protects healthy malaria-naive


Oct;74(10):5933-5942.

Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC, Walther M, et al. Safety of

recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines againstliver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2006 Apr

5;24(15):3026-3034.

HepB Core-Ag CSP VLP

Nardin EH, Oliveira GA, Calvo-Calle JM, Wetzel K, Maier C, Birkett AJ, et al. Phase Itesting of a malaria vaccine composed of hepatitis B virus core particles expressing

Plasmodium falciparum circumsporozoite epitopes. Infect.Immun. 2004

Nov;72(11):6519-6527.

Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Birkett A, et al.Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium

falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.

Infect.Immun. 2005 Jun;73(6):3587-3597.

Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T, Schmidt A, et al. Safety,immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132

formulated in Seppic ISA 720. Vaccine 2005 Jan 4;23(7):857-64.

Gregson AL, Oliveira G, Othoro C, Calvo-Calle JM, Thorton GB, Nardin E, et al. Phase Itrial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes

of Plasmodium falciparum circumsporozoite protein. PLoS One 2008 Feb 6;3(2):e1556.

RTS,S/AS02 + MVA CSP

Dunachie SJ, Walther M, Vuola JM, Webster DP, Keating SM, Berthoud T, et al. A

clinical trial of prime-boost immunisation with the candidate malaria vaccines

RTS,S/AS02A and MVA-CS. Vaccine 2006 Apr 5;24(15):2850-2859.


21/28


RTS,S/AS02 / DNA CSP

Epstein JE, Charoenvit Y, Kester KE, Wang R, Newcomer R, Fitzpatrick S, et al. Safety,tolerability, and antibody responses in humans after sequential immunization with a

PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.Vaccine 2004 Apr 16;22(13-14):1592-603.

Wang R, Epstein J, Charoenvit Y, Baraceros FM, Rahardjo N, Gay T, et al. Induction inhumans of CD8+ and CD4+ T cell and antibody responses by sequential immunization

with malaria DNA and recombinant protein. J.Immunol. 2004 May 1;172(9):5561-5569.

CSP long synthetic peptide

Lopez JA, Weilenman C, Audran R, Roggero MA, Bonelo A, Tiercy JM, et al. A

synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune

response in humans. Implications for vaccination strategies. Eur J Immunol2001;31(7):1989-98.

Audran R, Lurati-Ruiz F, Genton B, Blythman HE, Ofori-Anyinam O, Reymond C, et al.

The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malariavaccine candidate: a randomized controlled phase I trial. PLoS One 2009 Oct

2;4(10):e7304.

Genton B, D'Acremont V, Lurati-Ruiz F, Verhage D, Audran R, Hermsen C, et al.

Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malariavaccine PfCS102 to protect against challenge with P. falciparum. Vaccine 2010 Sep

14;28(40):6573-6580.

CSP DNA Immunization

Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, et al. Induction

of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

Science 1998;282(5388):476-80.

Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, et al. Safety,

tolerability and humoral immune responses after intramuscular administration of a

malaria DNA vaccine to healthy adult volunteers. Vaccine 2000;18(18):1893-901.

Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ, et al. Induction

of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA

vaccine. Proc.Natl.Acad.Sci.U.S.A. 2001 Sep 11;98(19):10817-10822.

Epstein JE, Gorak EJ, Charoenvit Y, Wang R, Freydberg N, Osinowo O, et al. Safety,tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria

vaccine via needle or needle-free jet injection, and comparison of intramuscular and


22/28


combination intramuscular/intradermal routes. Hum.Gene Ther. 2002 Sep 1;13(13):1551-

1560.

FP9 CSP + LSA-1 epitope/ MVA-CSP + LSA-1 epitope

Imoukhuede EB, Berthoud T, Milligan P, Bojang K, Ismaili J, Keating S, et al. Safetyand immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult

Gambian men. Vaccine 2006 Oct 30;24(42-43):6526-6533.

Walther M, Thompson FM, Dunachie S, Keating S, Todryk S, Berthoud T, et al. Safety,immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus

FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum

circumsporozoite protein. Infect.Immun. 2006 May;74(5):2706-2716.

DNA/MVA prime-boost Multi-Epitope (ME) string + TRAP

McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, et al.Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant

modified vaccinia virus Ankara in humans. Nat Med 2003 Jun;9(6):729-35.

Moorthy VS, Pinder M, Reece WH, Watkins K, Atabani S, Hannan C, et al. Safety and

immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African

adults. J Infect Dis 2003 Oct 15;188(8):1239-44.

Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, et al. A

randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP

against malaria infection in Gambian adults. PLoS Med 2004 Nov;1(2):e33.

Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, Skinner MA, et al.

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-monthreboosting vaccination, for malaria vaccination in gambian men. J Infect Dis 2004 Jun

15;189(12):2213-9.

Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, et al.

Differential immunogenicity of various heterologous prime-boost vaccine regimens using


Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, et al. A DNA

prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-relatedadhesion protein but not circumsporozoite protein partially protects healthy malaria-naive


Oct;74(10):5933-5942.

FP9 MVA prime-boost ME-TRAP


23/28


Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, et al.Differential immunogenicity of various heterologous prime-boost vaccine regimens using


Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, Todryk S, et al. A phase 2b

randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAPamong children in Kenya. PLoS Clin Trials 2006;1(6):e29.

Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, Lang T, et al. Immunogenicity ofthe candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-

erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.

Vaccine 2006 May 29;24(22):4709-4715.

Bejon P, Kai OK, Mwacharo J, Keating S, Lang T, Gilbert SC, et al. Alternating vectorimmunizations encoding pre-erythrocytic malaria antigens enhance memory responses in

a malaria endemic area. Eur.J.Immunol. 2006 Aug;36(8):2264-2272.

Bejon P, Peshu N, Gilbert SC, Lowe BS, Molyneux CS, Forsdyke J, et al. Safety Profileof the Viral Vectors of Attenuated Fowlpox Strain FP9 and Modified Vaccinia Virus

Ankara Recombinant for Either of 2 Preerythrocytic Malaria Antigens, ME-TRAP or the

Circumsporozoite Protein, in Children and Adults in Kenya. Clin Infect Dis 2006 Apr

15;42(8):1102-10.

Bejon P, Ogada E, Mwangi T, Milligan P, Lang T, Fegan G, et al. Extended follow-up

following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP

and MVA ME-TRAP among children in Kenya. PLoS One 2007 Aug 15;2(1):e707.

Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, Skinner MA, et al.Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month

reboosting vaccination, for malaria vaccination in gambian men. J Infect Dis 2004 Jun

15;189(12):2213-9.

RTS,S/AS02 and TRAP

No citation.

AMA-1 (Australia)

Saul A, Lawrence G, Allworth A, Elliott S, Anderson K, Rzepczyk C, et al. A human

phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidateapical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 2005 Apr

27;23(23):3076-3083.

RESA, MSP1, MSP2 (combination B)


24/28


Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, et al. Human phase Ivaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720

adjuvant. Vaccine 1999 Aug 6;17(23-24):3145-3159.

Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D, et al. Safety and

immunogenicity of a three-component blood-stage malaria vaccine in adults living in anendemic area of Papua New Guinea. Vaccine 2000;18(23):2504-11.

Lawrence G, Cheng QQ, Reed C, Taylor D, Stowers A, Cloonan N, et al. Effect ofvaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of

Plasmodium falciparum in non-immune volunteers. Vaccine 2000 Mar 17;18(18):1925-

1931.

Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, et al. A recombinantblood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective

pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis

2002 Mar 15;185(6):820-7.

Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, et al. Safety and

immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA)

against Plasmodium falciparum in Papua New Guinean children. Vaccine 2003 Dec

8;22(1):30-41.

Pfs25

Pvs25

Zou L, Miles AP, Wang J, Stowers AW. Expression of malaria transmission-blocking

vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Vaccine 2003Apr 2;21(15):1650-1657.

Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, et al. Phase 1

vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.

Vaccine 2005 May 2;23(24):3131-8.

Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, et al. Phase 1 trial of

malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with

montanide ISA 51. PLoS One 2008 Jul 9;3(7):e2636.

FMP-1 (MSP-1 42 3D7) + RTS,S (CSP)

Ogutu BR. A Double-blind, Randomized, Controlled, Phase IIb Field Trial in 12 to 47Month-old Children in Western Kenya to Evaluate the Efficacy, Safety and

Immunogenicity of the FMP1/AS02A Malaria Vaccine (WRAIRs MSP-1 Antigen

Adjuvanted in GlaxoSmithKline Biologicals AS02A) Versus Rabies Vaccine.

NMRC-MV-Ad-PfC


25/28


Abstract Only

http://www.astmh.org/AM/Template.cfm?Section=Meeting_Archives&Template=/CM/ContentDisplay.cfm&ContentID=1511

Abstract number 304

LSA-3 (inactive)

Nieman AE, de Mast Q, Roestenberg M, Wiersma J, Pop G, Stalenhoef A, et al. Cardiac

complication after experimental human malaria infection: a case report. Malar J

2009;8:277.

MuStDO5 (Multi-Stage DNA vaccine Operation, 5 antigens)

Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, et al. Boosting of

DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria

parasites. Infect.Immun. 2005 May;73(5):2863-2872.

PvRII

Devi YS, Mukherjee P, Yazdani SS, Shakri AR, Mazumdar S, Pandey S, et al.

Immunogenicity of Plasmodium vivax combination subunit vaccine formulated withhuman compatible adjuvants in mice. Vaccine 2007 Jul 9;25(28):5166-5174.

Yazdani SS, Shakri AR, Mukherjee P, Baniwal SK, Chitnis CE. Evaluation of immuneresponses elicited in mice against a recombinant malaria vaccine based on Plasmodium

vivax Duffy binding protein. Vaccine 2004 Sep 9;22(27-28):3727-3737.

Spf66

Lopez MC, Silva Y, Thomas MC, Garcia A, Faus MJ, Alonso P, et al. Characterization of

SPf(66)n: a chimeric molecule used as a malaria vaccine. Vaccine 1994 May;12(7):585-

591.

Noya O, Gabaldon Berti Y, Alarcon de Noya B, Borges R, Zerpa N, Urbaez JD, et al. A

population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria

vaccine in Venezuela. J.Infect.Dis. 1994 Aug;170(2):396-402.

Alonso PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H, et al.Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in

children in southern Tanzania. Lancet 1994 Oct 29;344(8931):1175-1181.

Sempertegui F, Estrella B, Moscoso J, Piedrahita L, Hernandez D, Gaybor J, et al. Safety,immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against

Plasmodium falciparum infection in a randomized double-blind placebo-controlled field

trial in an endemic area of Ecuador. Vaccine 1994 Mar;12(4):337-342.


26/28


Teuscher T, Schellenberg JR, Bastos de Azevedo I, Hurt N, Smith T, Hayes R, et al.

SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in

Tanzanians exposed to intense malaria transmission. Vaccine 1994 Mar;12(4):328-336.

Alonso PL, Tanner M, Smith T, Hayes RJ, Schellenberg JA, Lopez MC, et al. A trial of

the synthetic malaria vaccine SPf66 in Tanzania: rationale and design. Vaccine 1994Feb;12(2):181-186.

Lopez MC, Thomas MC, Olivares M, Alonso P, Alonso C. The effect of temperature onthe stability of the synthetic SPf(66)n malaria vaccine. Vaccine 1995 Sep;13(13):1180-

1182.

D'Alessandro U, Leach A, Drakeley CJ, Bennett S, Olaleye BO, Fegan GW, et al.

Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995 Aug

19;346(8973):462-467.

Ballou WR, Blood J, Chongsuphajaissidhi T, Gordon DM, Heppner DG, Kyle DE, et al.Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptidepolymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study.

Parasitology 1995;110 Suppl:S25-36.

Alonzo PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H, et al.Randomised trial of SPf66 vaccine against Plasmodium falciparum malaria in children in

southern Tanzania. Med.Trop.(Mars) 1995;55(4 Suppl):41-46.

Alonso PL, Smith TA, Armstrong-Schellenberg JR, Kitua AY, Masanja H, Hayes R, et al.

Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in

African children exposed to intense transmission of Plasmodium falciparum. J.Infect.Dis.1996 Aug;174(2):367-372.

D'Alessandro U. An efficacy trial of a malaria vaccine in Gambian infants and

comparison with insecticide-treated bednets. Ann.Trop.Med.Parasitol. 1996

Aug;90(4):373-378.

Valero MV, Amador R, Aponte JJ, Narvaez A, Galindo C, Silva Y, et al. Evaluation of

SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of

Colombia. Vaccine 1996 Oct;14(15):1466-1470.

Nosten F, Luxemburger C, Kyle DE, Ballou WR, Wittes J, Wah E, et al. Randomiseddouble-blind placebo-controlled trial of SPf66 malaria vaccine in children in

northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet 1996 Sep

14;348(9029):701-707.

Urdaneta M, Prata A, Struchiner CJ, Tosta CE, Tauil P, Boulos M. Safety evaluation of

SPf66 malaria vaccine in Brazil. Rev.Soc.Bras.Med.Trop. 1996 Sep-Oct;29(5):497-501.


27/28


Beck HP, Felger I, Huber W, Steiger S, Smith T, Weiss N, et al. Analysis of multiple

Plasmodium falciparum infections in Tanzanian children during the phase III trial of the

malaria vaccine SPf66. J.Infect.Dis. 1997 Apr;175(4):921-926.

Bojang KA, Obaro SK, Leach A, D'Alessandro U, Bennett S, Metzger W, et al. Follow-

up of Gambian children recruited to a pilot safety and immunogenicity study of themalaria vaccine SPf66. Parasite Immunol. 1997 Dec;19(12):579-581.

Nosten F, Luxemburger C, Kyle DE, Gordon DM, Ballou WR, Sadoff JC, et al. Phase Itrial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast Asia.

Am.J.Trop.Med.Hyg. 1997 May;56(5):526-532.

Migasena S, Heppner DG, Kyle DE, Chongsuphajaisiddhi T, Gordon DM, Suntharasamai

P, et al. SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in

Thailand. Acta Trop. 1997 Sep 30;67(3):215-227.

Bojang KA, Obaro SK, D'Alessandro U, Bennett S, Langerock P, Targett GA, et al. Anefficacy trial of the malaria vaccine SPf66 in Gambian infants--second year of follow-up.

Vaccine 1998 Jan;16(1):62-67.

Urdaneta M, Prata A, Struchiner CJ, Tosta CE, Tauil P, Boulos M. Evaluation of SPf66

malaria vaccine efficacy in Brazil. Am.J.Trop.Med.Hyg. 1998 Mar;58(3):378-385.

Lopera TM, Restrepo M, Blair S, Garcia HI. Humoral immune response to the anti-

malaria vaccine SPf66 in the Colombian Atrato River region. Mem.Inst.Oswaldo Cruz

1998 Jul-Aug;93(4):495-500.

Acosta CJ, Galindo CM, Schellenberg D, Aponte JJ, Kahigwa E, Urassa H, et al.Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI

scheme in Tanzania. Trop.Med.Int.Health 1999 May;4(5):368-376.

Schellenberg DM, Acosta CJ, Galindo CM, Kahigwa E, Urassa H, Masanja H, et al.

Safety in infants of SPf66, a synthetic malaria vaccine, delivered alongside the EPI.

Trop.Med.Int.Health 1999 May;4(5):377-382.

Metzger WG, Haywood M, D'Alessandro U, Drakeley CJ, Weiss H, Bojang K, et al.

Serological responses of Gambian children to immunization with the malaria vaccine

SPf66. Parasite Immunol. 1999 Jul;21(7):335-340.

Galindo CM, Acosta CJ, Schellenberg D, Aponte JJ, Roca A, Oettli A, et al. Humoral

immune responses during a malaria vaccine trial in Tanzanian infants. Parasite Immunol.

2000 Sep;22(9):437-443.

Kashala O, Amador R, Valero MV, Moreno A, Barbosa A, Nickel B, et al. Safety,

tolerability and immunogenicity of new formulations of the Plasmodium falciparum


28/28


malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

Vaccine 2002 May 22;20(17-18):2263-2277.

Date post:	14-Apr-2018
Category:	Documents
Upload:	jorge-palacio
View:	248 times
Download:	1 times

Rainbow Table Reference List

Documents